Evidence map›Paper›PMID 38184808›Full record

ArticleMolecular biotechnology2024

Mechanism of Hirudin-Mediated Inhibition of Proliferation in Ovarian Cancer Cells.

Junyan Kou, Liujie Gao, Liwei Ni, Tingting Shao, Jiyuan Ding

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Recent progress on formulations of hirudin.Pharmaceutical science advances · 2025
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Junyan KouOncology Department of Integrated Traditional Chinese and Western Medicine, Hangzhou Cancer Hospital, No. 34 Yanguan Lane, Ziyang Street, Shangcheng District, Hangzhou, 310000, Zhejiang Province, China.
Liujie GaoDepartment of Oncology & Hematology, Hangzhou Red Cross Hospital, Hangzhou, 310003, Zhejiang Province, China.
Liwei NiOncology Department of Integrated Traditional Chinese and Western Medicine, Hangzhou Cancer Hospital, No. 34 Yanguan Lane, Ziyang Street, Shangcheng District, Hangzhou, 310000, Zhejiang Province, China.
Tingting ShaoOncology Department of Integrated Traditional Chinese and Western Medicine, Hangzhou Cancer Hospital, No. 34 Yanguan Lane, Ziyang Street, Shangcheng District, Hangzhou, 310000, Zhejiang Province, China.
Jiyuan DingDepartment of Oncology & Hematology, Hangzhou Red Cross Hospital, Hangzhou, 310003, Zhejiang Province, China. HHYYDingjiyuan@126.com.ORCID http://orcid.org/0009-0007-2037-4551
Hangzhou Cancer Hospital · CNHangzhou Red Cross Hospital · CN

Funding

Traditional Chinese Medicine Science and Technology Program Project of Zhejiang Province 2022ZA140
6 · The paper itself

Abstract

To investigate the inhibitory effect of hirudin on the cell proliferation of human ovarian cancer A2780 cells by preventing thrombin and its underlying molecular mechanism. Cell Counting Kit-8 (CCK-8) method was used to detect the effect of different concentrations of hirudin and thrombin on the cell proliferation of A2780 cells. PAR-1 wild-type overexpression plasmid was constructed utilizing enzyme digestion identification, and it was transferred to A2780 cells. Sequencing and Western blot were used to detect the changes in PAR-1 protein expression. Western blot detection of PKCα protein phosphorylation in A2780 cells was performed. We also implemented quantitative PCR to detect the mRNA expression levels of epithelial-mesenchymal transition (EMT)-related genes, CDH2, Snail, and Vimentin, in A2780 cells. 1 μg/ml hirudin treatment maximally inhibited the promotion of A2780 cell proliferation by thrombin. Hirudin inhibited the binding of thrombin to the N-terminus of PAR-1, hindered PKCα protein phosphorylation in A2780 cells, and downregulated the mRNA expression levels of CDH2, Snail, and Vimentin. In conclusion, hirudin inhibits the cell proliferation of ovarian cancer A2780 cells, and the underlying mechanism may be through downregulating the transcription level of EMT genes, CDH2, Snail, and Vimentin. This study indicates that hirudin may have a therapeutic potential as an anti-cancer agent for ovarian cancer.

Indexed as

Cell ProliferationEpithelial-Mesenchymal TransitionHirudinsOvarian NeoplasmsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansPhosphorylationProtein Kinase C-alphaReceptor, PAR-1ThrombinVimentinHirudinsPRKCA protein, humanProtein Kinase C-alphaReceptor, PAR-1ThrombinVimentinEpithelial-mesenchymal transitionHirudinOvarian cancerProliferationThrombin

Identifiers

PMID38184808
OpenAlexW4390650976

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.